Stay updated with breaking news from Jeffrey boyd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Lets bring in michael ye and another health care analyst. Michael, first you to. Given the deals that we have seen, not just today but in the past, why do you believe a biomarine or vertex may be takeout targets down the line . Two reasons. One is if you looked at biotech valuations, theyre down 35 off the top in the last 6 to 8 months on political rhetoric that we talked about. So asset prices have come down and become a lot more attractive. The second point is that theres no change to the fact that Big Companies need commercial products and they need pipeline. Thats exactly what youre seeing. And what will those companies have that make them attractive you to or to potentially bottom . Les, we can hear you. Well get to you in a second. What makes them potential buyout candidates . Both vertex and biomerine have real revenue. Theyre out there right now plus pipelines. You get both of those with that. And so both of these companies ....
The yen soaring on the news. Does that excite you . With kelly here. Kelly can yes she loves currency stuff. Its crazy. Talking about 108 . Just the move. Look at that chart. I dont have a lot of insight. But i think it is remarkable that it can get whip sawed like that. Everybody piles in thinking it can only get weaker and then here we go. Live by the sword, die by the sword. Anyone putting their foot on the accelerate anywhere around the world is usually a boost and i thought really . This causes us to go down . Well the turnaround for japan. It was interesting when they did the negative rates thing in the first place. And everyones trying to do the same thing. But it was that moment they went negative you actually started to see things go the other way and it hasnt stopped since. When they go negative. Politicians do that a lot. They promise to not do that. I have to say two things. Can i compliment you this morning on two things . The tie and the haircut. Thank you. And dye job ho ....
Well break down all the mergers and acquisitions and wheel talk to miles white about his 25 billion of st. Jude. A strong Earnings Report after the bell yesterday, the company shattered estimates and is proposing a new sale structure. And well take a look at how the day on wall street is shaping up. Lets get to m a. The deal valuing st. Jude at 85 a share. Lets keep a close eye on abbott labs stock. They expect to add to earnings. Wheel have an interview with ceo white. And a crossborder hostile for medivation. We have plenty in the world of health care so to speak. Jim, lets start off with abbott. By the way, they also have this olear deal on tap. That kaem prior to them signing a confidential agreement late in february to get this deal done on st. Jude. Theyre talking big accretion. Im looking at a stock that is down pretty dramatically. Its a cash and share deal. So it is going to have the effect of hurting the overall value o ....